secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001437749-25-026511
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q2 rev $39.7M; norovirus antibodies up 141%; COVID trial stopped at 5K enrolled
--------------------------------------------------------------------------------

- Q2 2025 revenue $39.7M (vs $6.4M YoY); net loss $15.0M ($0.07/sh) vs $16.5M ($0.09/sh).
- Positive norovirus Phase 1: second-gen constructs raised GI.1 blockers 141%, GII.4 94% vs first-gen.
- COVID-19 Phase 2b enrollment halted Aug 5 at ~5,000 of planned 10,000; follow-up continues through late 2026.
- Cash $26.3M; runway into Q1 2026; exploring partnerships and non-dilutive funding to extend.
- Special meeting Sep 5 to vote on reverse stock split (1:5 to 1:20) for Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/0001437749-25-026511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/vxrt20250813_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer